Lv1
26 积分 2026-08-24 加入
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
10小时前
待确认
Atrasentan in Patients with IgA Nephropathy
10小时前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet
15小时前
已完结